An update on the controlled drug delivery approach for treating osteoporosis
Osteoporosis is a major concern as it is affecting majority of the population worldwide. It occurs due to a greater increase in bone resorption than bone formation. Osteoporosis literally results in abnormally porous bone that is compressible, like a sponge. This disorder of the skeleton weakens the bone and results in frequent fractures in the bones. Osteoporosis significantly affects the quality of life of patients affected by it. Scientists are trying to explore novel treatment approaches for carrying therapeutic agents so as to reinstate bone remodeling homeostasis.
The traditional therapy includes well-established antiresorptive and anabolic agents like estrogen, estrogen analogs, bisphosphonates, calcitonin, and parathyroid hormone, along with novel modulators and antibodies, which are mainly taken via oral, intravenous or subcutaneous route. These therapeutic agents may provide benefit to the patients but also offer patient nonconformity and several severe adverse reactions.
Osteoporosis and linked fracture risk can be effectually treated by the “Controlled drug delivery” approach. The polymeric, targeted and active release systems prolong half-life of the drugs by providing protection against early degradation and improves the extent of absorption and simultaneously offers protracted, continuous, or intermittent release at therapeutic doses.